李嘉诚视频“现身”

Core Viewpoint - The collaboration between Li Ka-shing Foundation and Temasek Trust to introduce Histotripsy technology for cancer treatment in Singapore is a significant advancement in medical innovation aimed at improving patient outcomes [1][2]. Group 1: Introduction of Histotripsy Technology - Histotripsy, a non-invasive ultrasound technology for tumor treatment, is being introduced to two hospitals in Singapore [1]. - The technology aims to provide hope and reduce pain for cancer patients, allowing for quicker recovery [2]. Group 2: Li Ka-shing's Involvement - Li Ka-shing expressed his honor in collaborating with Temasek Trust and emphasized the importance of medical innovation in combating cancer [2]. - He described Histotripsy as "incredible" and highlighted its potential to shatter cancer cells without radiation or ablation [2]. Group 3: Future Prospects - Since the arrival of the first machine in Hong Kong in September 2024, 50 liver cancer patients have successfully undergone treatment [2]. - Li Ka-shing anticipates that the development of this technology will benefit patients in Singapore and beyond [2].